A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

Also called NCT07662109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07662109
  • EU CT 2025-523941-81-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, China, Czechia, Denmark, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, Poland, Puerto Rico, Slovakia, South Africa, South Korea, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07662109. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Acronym
Eluminate-5
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Elecoglipron-matched placebo
Intervention (Drug)
Dapagliflozin-matched placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07662109
Content hash
2e5e3bad83a0767b37e66197dda8e1f18429cd7db9f17be72d13cc3300c98831